Childhood cancer survivors: improving our practice today to reduce late, major surgical interventions tomorrow

Olga Nigro, Giovanna Gattuso, Giovanna Sironi, Marta Podda, Elisabetta Schiavello, Filippo Spreafico, Monica Terenziani

Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Correspondence to: Monica Terenziani, MD. Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian n. 1, 20133 Milan, Italy. Email: monica.terenziani@istitutotumori.mi.it.


Keywords: Childhood cancer survivors (CCSs); late surgery; late effects

Submitted Aug 03, 2023. Accepted for publication Dec 11, 2023. Published online Jan 05, 2024.
doi: 10.21037/tp-23-417
View this article at: https://dx.doi.org/10.21037/tp-23-417

Approximately 35,000 children and adolescents in Europe (1), and 450,000 in the US (2) are diagnosed with cancer every year. With more new technologies, advances in surgical techniques and innovative drug therapies being developed, childhood cancer survivors (CCSs) to date account for more than 80% of the patients treated for pediatric tumors (3-5). As these patients age and reach middle and late ages, they are at high risk of long-term side effects, including secondary cancers, and premature mortality (6).

Recently, Dieffenbach et al. (7), analyzing data from the Childhood Cancer Survivor Study (CCSS, retrospective cohort study with longitudinal prospective follow-up of 25,656 5-year survivors of childhood cancer, who were diagnosed between 1970 and 1999, and matched with a group of 5,045 siblings), conducted a full examination of the associations between specific childhood cancer treatments and the burden of late surgical interventions.

The authors observed a significant burden of late major surgical interventions: cardiovascular, spine, endocrine, central nervous system (CNS), respiratory, genitourinary, gastrointestinal, musculoskeletal, head and neck, breast interventions. The rate of these interventions was higher compared with that of their siblings (7) and these happened at a younger age (more than 10 year earlier than in the comparison group). The authors reported detailed risk categories. The risk of cumulative burden of major surgical interventions was higher in female versus male survivors, in those diagnosed in the 1990s versus those diagnosed on the 1970s, in those treated with locoregional surgery or radiotherapy, and in Hodgkin lymphoma and bone sarcoma patients (7).

Surgery plays a fundamental role in the treatment of childhood cancer, also in the management of long-term sequelae (8), and the result of high cumulative late major interventions was expected due to these reasons. Treatment of secondary malignancies, bowel obstruction after surgical adhesions or abdominal radiotherapy, the shunt replacement or revision in CNS survivors, correction of spinal deformity subsequent to radiotherapy or laminectomy, many limb salvage procedures, prosthetic substitutions, complications of amputations, and surgical treatment of osteonecrosis are some of the long lists of these late surgical interventions.

The greatest merit of this work (7) is the detailed information available, to underline the extent of the issue (28,202 surgical intervention versus 4,110 in the siblings’ cohort), which had been poorly quantified up to this point.

When comparing data from survivors treated in the 1970s and those treated in the 1990s, an increasing cumulative burden of late major surgery emerges in the more recent group; this is probably due to an increased number of survivors of high-risk disease who underwent intense multimodal therapy, with subsequent occurrence of late, treatment-related complications (7). Moreover, Dieffenbach et al. shows how the cumulative burden of major surgical interventions is higher among female
regardless of long-term toxicities.

still an increased event-free survival and overall survival or higher risk subgroups for which the main objectives are cohort.

we would hope for a decrease in the burden of late surgical subtypes of CNS tumors), where possible (7). Therefore, using proton beam radiotherapy instead of photons in some the indication of radiotherapy in Hodgkin's lymphoma, (i.e., avoiding prophylactic radiotherapy in ALL, reducing anthracycline dosages and avoiding/reducing radiotherapy some treatments have been implemented by using lower effects is expected to translate into a future lesser burden, particularly in selected groups of patients. In recent years, some treatments have been implemented by using lower anthracycline dosages and avoiding/reducing radiotherapy (i.e., avoiding prophylactic radiotherapy in ALL, reducing the indication of radiotherapy in Hodgkin's lymphoma, using proton beam radiotherapy instead of photons in some subtypes of CNS tumors), where possible (7). Therefore, we would hope for a decrease in the burden of late surgical intervention in Hodgkin's survivors as compared to this old cohort.

The same cannot be said for patients in other disease or higher risk subgroups for which the main objectives are still an increased event-free survival and overall survival regardless of long-term toxicities.

Diefenbach et al. reported that locoregional surgery or radiotherapy were associated with late surgical intervention in the same body region or organ system (7).

For example, in bone sarcomas, it is still necessary to perform extensive surgeries involving prosthetics and requiring further surgical adjustments during adult age. In most of these patients, when surgery fails or is impossible (i.e., axial localizations), radiotherapy cannot be avoided or may be necessary in combination with other treatments, such as in cases of Ewing sarcoma. This combination of surgery and radiotherapy can cause further hypotrophy and dysmetries with consequent need for other future surgical procedures to correct the deformity. Speaking about late surgery in CCSs, we must certainly not forget the important role that reconstructive surgery plays in particular groups of patients (i.e., patients who have undergone previous demolitive surgery). In this context, many patients who would usually be treated with photons could be treated with protons or carbon ions, ideally reducing late effects. However, data on very long-term late effects of these relatively new techniques are not yet available in the childhood cancers (CCs), and we cannot predict with certainty whether these may cause a reduction of burden in the late, major surgical intervention.

These patients could be also at risk for low bone mineral density (BMD), caused by disturbances in bone metabolism, that may develop as a consequence of many factors (i.e., treatments, cancer itself, wrong diet, genetic susceptibility), and reduced physical activity during and after the disease (13). In addition, BMD may be a final result of gonadal failure after exposure to abdomino/pelvic radiation or alkylating agents, or as a result of hypothalamic-pituitary deficiencies after CNS irradiation. Although reduced BMD is usually asymptomatic, data in general population has shown that it leads to an increased risk of fractures, which results in acute and sometimes long-term morbidity, and in selected cases may require surgical interventions (13).

To date, there is now a great attention to promote exercise and its related benefits (14-17). Being long-term survivors, therefore, cancer patients are always encouraged to live a normal life (17). Regular exercise can help reduce the deterioration of physical function (15-17). The benefits of exercise for patients with cancer are increasingly being investigated; the inactivity could be a contributor of death, and probably has a relevant role in the rising incidence of non-communicable diseases, including certain types of cancer and cancer-related acute and late morbidity (17). Survivors who exercise are exposed to a lower risk of further major surgeries, cardiovascular interventions, or bariatric surgeries. Exercise should be supervised and tailored to the individual to avoid the necessity of orthopedic intervention (i.e., traumatic fractures, muscular strains). This concept is particularly relevant considering the high prevalence and severity of bone density deficits observed in CCs.

Due to these considerations, it is essential to encourage survivors to adopt a healthy lifestyle (i.e., the avoidance of smoking, alcohol, physical inactivity, and caffeine consumption). Strain et al. (18), showed that the health benefits of weight loss are well established. If other methods previous failed, we have no evidence that weight loss surgery cannot be offered to patients who have had a previous diagnosis and successful treatment of cancer.
As a final point, the economic aspect must certainly be taken into account for single patient in terms of the economic and social consequences of the disease as well as for Health systems. Fidler-Benaoudia et al. (19) observed that compared with those in the UK, CCSs in the United States had worse outcomes as the time since diagnosis increased. This could be related to a suboptimal follow-up care for survivors, due to the lack of insurance, identified as an important predictor: CCSs are more likely to skip a necessary examination or medical treatment due to cost issues, and surgical procedures could be particularly expensive. In Health systems, this burden of late surgeries undoubtedly also represents an economic burden both for the individual and the society (20). There is, therefore, a situation whereby, both the individual patient and the economic system in general, suffer. This is not true for other health systems, in which the economic cost of late surgeries may only be cover by a few. It is also important to remember that frequently, due to the health burden, CCSs are individuals who have some difficulties in finding jobs, who most often live with their native family, have limited independency and, therefore, may represent a burden.

In conclusion, CCSs are complex patients and, thanks to new cancer therapies, their numbers will increase more and more in the coming years. Evidence-based guidelines for the management of CCSs are offered in many issues. The outstanding work, initiated in 2010, by International Later Effects of Childhood Cancer Guideline Harmonization Group allows a shared and common strategy for the surveillance of late effects in CCs (21) to be established, and awareness on this topic to grow. The CCSS study focuses on a sometimes poorly quantified burden of survivorship, adding a new important insight on the already complex needs of long-term cancer survivors. Moreover, up-to-date guidelines, e.g., from the IGHG (International Late Effects of Childhood Cancer Guideline Harmonization Group), exist, the problem being that they are not broadly implemented (22).

We must, therefore, help physicians and educate CCs in recognizing early late effects requiring major surgeries, inform the medical communities of this high-cost need and evaluate changes, if any, in the recent CCs cohorts of this long-term burden.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Translational Pediatrics. The article has undergone external peer review.

Peer Review File: Available at https://tp.amegroups.com/article/view/10.21037/tp-23-417/prf

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-23-417/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References


© Translational Pediatrics. All rights reserved.


